Skip to Main Content
Try STAT+ TODAY
Trending:
STAT+
Health
Biotech
First Opinion
The Readout

Pfizer’s CAR-T move & Intra-Cellular’s long odds

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan April 4, 2018

Reprints
The READOUT
Alex Hogan/STAT

The Readout for April 04, 2018

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

FDA’s letter to medical device maker iRhythm is a…
FDA’s letter to medical device maker iRhythm is a warning for the industry
Fentanyl isn’t just causing overdoses. It’s making it harder…
Fentanyl isn’t just causing overdoses. It’s making it harder to start addiction treatment
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain
How Biogen got Aduhelm approved, Sanofi’s future in mRNA,…
How Biogen got Aduhelm approved, Sanofi’s future in mRNA, & Celgene’s endless saga

Recommended Stories